LEADING THE FUTURE OF CELL THERAPY
WITH OUR AlloCAR T™ PLATFORM

INNOVATION

  • Multiplex gene-engineering and gene-editing capabilities
  • Proprietary lymphodepletion platform
  • State-of-the-art manufacturing
  • Opportunity for product optimization

PIPELINE

  • CD19
    • ALLO-501 – Phase 1
    • ALLO-501A – Phase 1
  • BCMA
    • ALLO-715 – Phase 1
    • ALLO-715 + nirogacestat – Phase 1
    • ALLO-605 – Phase 1
  • CD70
    • ALLO-316 – Phase 1

LEADERSHIP

  • A highly experienced management team that includes key pioneers of CAR T cell therapy
  • Approximately 275 employees singularly focused on the development of AlloCAR T™ therapy
  • Allogene is proud to have approximately 50% of our senior leadership team and entire organization identify as female.

WE DON’T JUST SEE THE FUTURE.

WE KNOW HOW TO GET THERE.

Our mission is to create and lead the next revolution in cancer treatment by delivering to patients the first allogeneic CAR T cell (AlloCAR T™) therapies for blood cancers and solid tumors

WHY ALLOGENEIC CELL THERAPY HAS THE
POTENTIAL TO LEAD THE REVOLUTION

ACCESS

  • Potential to treat all
    eligible patients
  • Repeat dosing, if needed
  • No need for complex logistics

COST

  • Scalable and efficient manufacturing
  • Potential to treat 100+ patients from a single manufacturing run
  • Lower ancillary costs of care

SPEED/RELIABILITY

  • Off-the-shelf for on-demand treatment
  • Less product variability, made from healthy T cells

OUR VIRTUAL EXHIBIT

Our Virtual Exhibit

This is a virtual environment with interactive information on the latest advances in AlloCAR T™ therapy as well as our pipeline, clinical trials, and online resources.

OUR PARTNERS

Cellectis
Notch Therapeutics
Servier
Spring Works Therapeutics

LATEST NEWS

©2020 ALLOGENE THERAPEUTICS